A Phase 3 interventional study of Gabapentin Extended Release tablets and Placebo in Neuralgia,Postherpetic, sponsored by Depomed. Completed at 39 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.
Sponsored by Depomed · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Neuralgia, Postherpetic with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia, Postherpetic · United States.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, this one is the 4th largest by enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2008, is one of 8 in phase 3, and was the 23rd registered.
197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.
Browse Neuralgia, Postherpetic studies →4 of the 60 studies in Neuralgia, Postherpetic with a site in United States are open now. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 22–80
University of Minnesota · Sites in United States
Ages 22+
Neurodawn Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–45 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1993; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 94 across 163 interventional studies indexed under Neuralgia, Postherpetic.
Median enrollment 93 across the 56 interventional studies, 201 across the 3 observational. Of the 51 that completed or were terminated, 22 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.
Depomed has 3 studies filed under Neuralgia, Postherpetic — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia, Postherpetic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 60 studies in Neuralgia, Postherpetic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.
The primary study objective is to assess the relative efficacy of G-ER dosed once daily (1800 mg following the evening meal), versus placebo in reducing the mean daily pain score from the baseline week to the end of the efficacy treatment period (Treatment Week 10) in patients with PHN.
Secondary efficacy measures will include changes from baseline in mean weekly sleep interference scores, Short-Form McGill Pain Questionnaire (SF-MPQ), the Neuropathic Pain Scale (NPS), Brief Pain Inventory (BPI), Patient Global Impression of Change (PGIC), and Investigator-Rated Clinical Global Impression of Change (CGIC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gabapentin - Extended Release
Drug: Gabapentin Extended Release tablets
Sugar pill
Drug: Placebo
Once-Daily; 300 mg and 600 mg tablets
Once daily; 300 mg and 600 mg tablets
Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).
Time frame: 10 weeks
Patient Global Impression of Change (PGIC)
Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
Time frame: 10 weeks
Clinical Global Impression of Change (CGIC)
Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
Time frame: 10 weeks
Average Daily Sleep Interference Score
Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).
Time frame: 10 weeks
Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10).
Time frame: 10 weeks
Recruitment period was from March 2008 through May 2009.
| Milestone | G-ER | Placebo |
|---|---|---|
| Started | 221 | 231 |
| Safety & efficacy of gabapentin er | 186 | 194 |
| 379 | 186 | 194 |
| Completed | 185 | 192 |
| Not completed | 36 | 39 |
| Withdrew: Other reason | 4 | 6 |
| Withdrew: Adverse event | 19 | 8 |
| Withdrew: Lack of efficacy | 7 | 12 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 9 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).
| Scores on a scale | G-ER | Placebo |
|---|---|---|
| Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score | -2.12 ± 0.17 | -1.63 ± 0.16 |
Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
| Participants | G-ER | Placebo |
|---|---|---|
| Patient Global Impression of Change (PGIC) | 94 | 77 |
Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).
| Participants | G-ER | Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGIC) | 97 | 78 |
Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).
| Scores on a scale | G-ER | Placebo |
|---|---|---|
| Average Daily Sleep Interference Score | -2.30 ± 0.16 | -1.59 ± 0.15 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10).
| Scores on a scale | G-ER | Placebo |
|---|---|---|
| Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score | -2.40 ± 0.17 | -1.85 ± 0.17 |
Collected over 11 weeks (plus 30 days for SAEs). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-ER | — | 4/221 (1.8%) | 92/221 (41.6%) |
| Placebo | — | 6/231 (2.6%) | 63/231 (27.3%) |
| Event | G-ER | Placebo |
|---|---|---|
| Left arm fractureMusculoskeletal and connective tissue disorders | 1/221 | 1/231 |
| OsteochondrosisMusculoskeletal and connective tissue disorders | 1/221 | 0/231 |
| Pancoast tumorRespiratory, thoracic and mediastinal disorders | 1/221 | 0/231 |
| Pancreatitis chronicGastrointestinal disorders | 1/221 | 0/231 |
| Cardiac failure congestionCardiac disorders | 0/221 | 1/231 |
| CellulitisSkin and subcutaneous tissue disorders | 0/221 | 1/231 |
| HematuriaRenal and urinary disorders | 0/221 | 1/231 |
| Myocardial infarctionCardiac disorders | 0/221 | 1/231 |
| ThrombophlebitisVascular disorders | 0/221 | 1/231 |
| Event | G-ER | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 25/221 | 4/231 |
| SomnolenceNervous system disorders | 12/221 | 7/231 |
| HeadacheNervous system disorders | 10/221 | 9/231 |
| NauseaGastrointestinal disorders | 10/221 | 7/231 |
| Peripheral edemaGeneral disorders | 7/221 | 1/231 |
| DiarrheaGastrointestinal disorders | 6/221 | 5/231 |
| Abdominal pain upperGastrointestinal disorders | 3/221 | 6/231 |
| NasopharyngitisInfections and infestations | 5/221 | 6/231 |
| Dry mouthGastrointestinal disorders | 4/221 | 2/231 |
| DyspepsiaGastrointestinal disorders | 4/221 | 1/231 |
| Age Continuous(years) | G-ER | Placebo | Total |
|---|---|---|---|
| Mean | 65.3 ± 13.3 | 65.9 ± 11.1 | 65.6 ± 12.2 |
| Age, Customized(participants) | G-ER | Placebo | Total |
|---|---|---|---|
| <65 years | 81 | 89 | 170 |
| 65 to 74 years | 82 | 86 | 168 |
| >=75 years | 57 | 55 | 112 |
| Sex: Female, Male(Participants) | G-ER | Placebo | Total |
|---|---|---|---|
| Female | 134 | 147 | 281 |
| Male | 86 | 83 | 169 |
| Race/Ethnicity, Customized(Participants) | G-ER | Placebo | Total |
|---|---|---|---|
| Caucasian | 196 | 204 | 400 |
| Black | 10 | 6 | 16 |
| Asian | 1 | 2 | 3 |
| Other | 13 | 18 | 31 |
The record gives a start of Mar 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Depomed